loading page

Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma
  • +29
  • Antonio Nieto García,
  • Teresa Garriga-Baraut,
  • Ana Maria Plaza,
  • María Nieto Cid,
  • Javier Torres-Borrego,
  • Mar Folque,
  • Jaime Lozano,
  • Montserrat Bosque,
  • Laura Moreno-Galarraga,
  • Miguel Tortajada,
  • Cristina Rivas Juesas,
  • María Penín Antón,
  • María Araceli Caballero-Rabasco,
  • Mirella Gaboli,
  • Alejandro López Neyra,
  • Juan Navarro Morón,
  • Andrea Freixa,
  • Laura Valdesoiro Navarrete,
  • Esther Ballester Asensio,
  • Verónica Sanz Santiago,
  • Raquel Romero,
  • Álvaro Gimeno Díaz de Atauri,
  • Alfredo Valenzuela Soria,
  • Mercedes Sánchez Mateos,
  • José Batlles Garrido,
  • Anselmo Andrés Martín,
  • Elena Campos Alonso,
  • Carmen Aragón Fernández,
  • Elena Vázquez Rodríguez,
  • Luz Martínez Pardo,
  • Genoveva del Río Camacho,
  • Ángel Mazón Ramos
Antonio Nieto García
Hospital Universitari i Politècnic La Fe

Corresponding Author:nieto_ant@gva.es

Author Profile
Teresa Garriga-Baraut
Hospital Universitari Vall d'Hebron
Author Profile
Ana Maria Plaza
Hospital Sant Joan de Deu
Author Profile
María Nieto Cid
Hospital Universitari i Politècnic La Fe
Author Profile
Javier Torres-Borrego
Reina Sofía Children’s University Hospital. Pediatrics Clinical Management Unit.
Author Profile
Mar Folque
Hospital Sant Joan de Déu, Universitat de Barcelona
Author Profile
Jaime Lozano
Hospital Sant Joan de Deu
Author Profile
Montserrat Bosque
Pediatric Allergology and Pneumology Unit, Hospital de Sabadell, Barcelona, Spain. Universitat Autònoma de Barcelona (UAB)
Author Profile
Laura Moreno-Galarraga
Complejo Hospitalario de Navarra
Author Profile
Miguel Tortajada
Hospital Universitario Doctor Peset
Author Profile
Cristina Rivas Juesas
Hospital de Sagunto
Author Profile
María Penín Antón
Hospital Universitario Príncipe de Asturias
Author Profile
María Araceli Caballero-Rabasco
Hospital del Mar
Author Profile
Mirella Gaboli
Hospital Universitario Virgen del Rocío
Author Profile
Alejandro López Neyra
Hospital Universitario Ramón y Cajal
Author Profile
Juan Navarro Morón
Hospital Costa del Sol
Author Profile
Andrea Freixa
Hospital Universitari Vall d'Hebron
Author Profile
Laura Valdesoiro Navarrete
Consorcio Corporacion Sanitaria Parc Tauli
Author Profile
Esther Ballester Asensio
Hospital Universitario Doctor Peset
Author Profile
Verónica Sanz Santiago
Hospital Infantil Universitario Niño Jesús
Author Profile
Raquel Romero
Hospital Universitario San Cecilio
Author Profile
Álvaro Gimeno Díaz de Atauri
Hospital Universitario 12 de Octubre
Author Profile
Alfredo Valenzuela Soria
Hospital Universitario Virgen de las Nieves
Author Profile
Mercedes Sánchez Mateos
Hospital Universitario Puerta del Hierro Majadahonda
Author Profile
José Batlles Garrido
Hospital Universitario Torrecárdenas
Author Profile
Anselmo Andrés Martín
Hospital Universitario Virgen Macarena
Author Profile
Elena Campos Alonso
Hospital Público Comarcal de La Merced
Author Profile
Carmen Aragón Fernández
Hospital Universitario de Jerez de la Frontera
Author Profile
Elena Vázquez Rodríguez
Hospital Universitario Nuestra Señora de Valme
Author Profile
Luz Martínez Pardo
Complejo Hospitalario de Jaén
Author Profile
Genoveva del Río Camacho
Hospital Universitario Fundación Jiménez Díaz
Author Profile
Ángel Mazón Ramos
Hospital Universitari i Politècnic La Fe
Author Profile

Abstract

Background: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow-up and/or number of patients included were limited. We aim to describe the long-term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real-life cohort reported to date. Methods: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients <18 years and initiating omalizumab between 2006-2018, from the year prior to omalizumab initiation to discontinuation or last available follow-up. The primary outcome was the evolution of the annual number of moderate-to-severe exacerbations compared to the baseline period. Results: Of the 484 patients included, 101 (20.9%) reached six years of treatment. The mean±standard deviation number of exacerbations decreased during the first year of treatment (7.9±6.6 to 1.1±2.0, p<0.001) and remained likewise for up to six years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution. Conclusion: In this large, long-term, observational study, moderate-to-severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long-term, along with a good safety profile. Our results position omalizumab as an effective long-term treatment in pediatric patients with severe persistent allergic asthma.
26 Oct 2020Submitted to Pediatric Allergy and Immunology
30 Oct 2020Reviewer(s) Assigned
17 Nov 2020Review(s) Completed, Editorial Evaluation Pending
18 Nov 2020Editorial Decision: Revise Minor
15 Feb 20211st Revision Received
16 Feb 2021Review(s) Completed, Editorial Evaluation Pending
18 Feb 2021Editorial Decision: Accept